| Literature DB >> 33081700 |
Quan Cai1, Si-Yao Du2, Si Gao2, Guo-Liang Huang2, Zheng Zhang2, Shu Li2, Xin Wang2, Pei-Ling Li2, Peng Lv2, Gang Hou3, Li-Na Zhang4.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic. According to the diagnosis and treatment guidelines of China, negative reverse transcription-polymerase chain reaction (RT-PCR) is the key criterion for discharging COVID-19 patients. However, repeated RT-PCR tests lead to medical waste and prolonged hospital stays for COVID-19 patients during the recovery period. Our purpose is to assess a model based on chest computed tomography (CT) radiomic features and clinical characteristics to predict RT-PCR negativity during clinical treatment.Entities:
Keywords: COVID-19; Computed tomography; Quantitative; RT-PCR; Radiomics
Mesh:
Substances:
Year: 2020 PMID: 33081700 PMCID: PMC7573533 DOI: 10.1186/s12880-020-00521-z
Source DB: PubMed Journal: BMC Med Imaging ISSN: 1471-2342 Impact factor: 1.930
Fig. 1The operating mode diagram of Fangcang Shelter Hospital in our study (a); the flow diagram summarizing the selection of the enrolled patients (b). N negative, P positive
Fig. 2The process of model establishment
Fig. 3CT images for cases in the RT-PCR-negative and RT-PCR-positive groups. The CT exams were performed on the 31st, 23rd, 24th and 22nd days from symptom onset for case 1–4, respectively. The two groups have a great overlap in original CT images and are difficult to be distinguished by eyes. After deep learning-based lobe and lesion segmentation, the radiomic feature maps of the lesion are calculated. For example, we can observe that original_firstorder_Minimum of the RT-PCR-negative group seems higher than the RT-PCR-positive group
Clinical characteristics of the RT-PCR-negative and RT-PCR-positive groups
| Variables | Total (n = 203) | Training dataset (n = 141) | Testing dataset (n = 62) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Negative (n = 122) | Positive (n = 81) | Negative (n = 85) | Positive (n = 56) | Negative (n = 37) | Positive (n = 25) | ||||
| General characteristics | |||||||||
| Age (years) | 52 (41, 58) | 49 (39, 57) | 0.325 | 52 (41, 61) | 51 (39, 58) | 0.551 | 52 (41, 56) | 46 (38, 56) | 0.315 |
| Gender | 0.343 | 0.191 | 0.800 | ||||||
| Female, n (%) | 70 (57.38) | 41 (50.62) | 49 (57.65) | 26 (46.43) | 21 (56.76) | 15 (60.00) | |||
| Male, n (%) | 52 (42.62) | 40 (49.38) | 36 (42.35) | 30 (53.57) | 16 (43.24) | 10 (40.00) | |||
| Time interval from symptoms onset to CT exams (days) | 23 (18, 30) | 16 (10, 22) | < 0.001 | 22 (18, 30) | 17 (11, 22) | < 0.001 | 25.16 ± 8.45 | 15.52 ± 7.51 | |
| Comorbidities | |||||||||
| Diabetes, n (%) | 9 (7.38) | 1 (1.23) | 0.099 | 7 (8.24) | 1 (1.79) | 0.212 | 2 (5.41) | 0 (0.00) | 0.511 |
| Hypertension, n (%) | 20 (16.39) | 10 (12.35) | 0.426 | 13 (15.29) | 9 (16.07) | 0.901 | 7 (18.92) | 1 (4.00) | 0.183 |
| Cardiovascular disease, n (%) | 1 (0.82) | 1 (1.23) | 1.000 | 1 (1.18) | 1 (1.79) | 1.000 | 0 (0.00) | 0 (0.00) | 1.000 |
| COPD, n (%) | 4 (3.28) | 2 (2.47) | 0.929 | 2 (2.35) | 1 (1.79) | 0.713 | 2 (5.41) | 1 (4.00) | 0.726 |
| Chronic liver disease, n (%) | 1 (0.82) | 0 (0.00) | 1.000 | 1 (1.18) | 0 (0.00) | 1.000 | 0 (0.00) | 0 (0.00) | 1.000 |
| Cancers, n (%) | 3 (2.46) | 1 (1.23) | 0.921 | 1 (1.18) | 1 (1.79) | 1.000 | 2 (5.41) | 0 (0.00) | 0.511 |
| Vital signs* | |||||||||
| Heart rate (beats/minute) | 83 (76, 90) | 85 (76, 90) | 0.650 | 83 (74, 90) | 85 (78, 89) | 0.432 | 84.51 ± 10.90 | 83.40 ± 14.06 | 0.727 |
| Systolic blood pressure (mmHg) | 127 (121, 135) | 128 (120, 134) | 0.637 | 126 (121, 133) | 129 (121, 135) | 0.822 | 129.43 ± 11.90 | 126.40 ± 12.53 | 0.339 |
| Diastolic blood pressure (mmHg) | 78 (74, 84) | 79 (74, 84) | 0.621 | 78 (73, 84) | 79 (72, 85) | 0.420 | 79 (75, 87) | 80 (76, 83) | 0.841 |
| Respiratory rate (times/minute) | 19 (18, 20) | 19 (18, 20) | 0.430 | 19 (18, 20) | 19 (18, 20) | 0.703 | 19 (18, 20) | 19 (19, 20) | 0.393 |
| Blood oxygen saturation (%) | 96 (96, 97) | 96 (96, 98) | 0.887 | 96 (96, 97) | 96 (96, 98) | 0.654 | 97 (96, 98) | 96 (96, 97) | 0.621 |
| Laboratory indicators* | |||||||||
| White blood cell count (× 109/L) | 5.19 (4.62, 6.27) | 5.10 (4.18, 5.86) | 0.194 | 5.16 (4.53, 6.27) | 5.00 (4.11, 5.61) | 0.298 | 5.40 (4.75, 6.23) | 5.19 (4.40, 6.18) | 0.478 |
| Neutrophil count (× 109/L) | 3.13 (2.66, 3.75) | 2.79 (2.34, 3.46) | 0.061 | 3.14 (2.46, 3.73) | 2.83 (2.33, 3.46) | 0.166 | 3.11 (2.72, 3.87) | 2.79 (2.31, 3.49) | 0.192 |
| Lymphocyte count (× 109/L) | 1.64 (1.33, 1.97) | 1.66 (1.30, 2.01) | 0.964 | 1.58 (1.33, 1.91) | 1.60 (1.26, 2.00) | 0.982 | 1.76 (1.43, 2.02) | 1.78 (1.43, 2.06) | 0.914 |
| Hemoglobin count (g/L) | 127 (118, 140) | 129 (118, 139) | 0.576 | 126.89 ± 16.99 | 131.46 ± 15.33 | 0.107 | 131 (121, 141) | 122 (115, 133) | 0.092 |
| Platelet count (× 109/L) | 232 (180, 279) | 219 (183, 283) | 0.469 | 226 (177, 281) | 219 (172, 263) | 0.565 | 240 (187, 277) | 215 (191, 288) | 0.651 |
| NLR | 1.83 (1.49, 2.40) | 1.77 (1.34, 2.16) | 0.160 | 1.91 (1.43, 2.50) | 1.79 (1.36, 2.25) | 0.357 | 1.82 (1.57, 2.13) | 1.62 (1.24, 2.02) | 0.187 |
Bold with p value < 0.05. Categorical variables are presented as numbers (percentages). Quantitative variables are presented as the mean ± standard deviation or median (25% percentile, 75% percentile) according to normality test results
COPD chronic obstructive pulmonary disease, NLR neutrophil/lymphocyte ratio
*Normal range: heart rate, 60–100 beats/minute; Systolic blood pressure, 90–140 mmHg; Diastolic blood pressure, 60–90 mmHg; Respiratory rate, 12–20 times/minute; Blood oxygen saturation, 95–100%; White blood cell count, 3.50–9.50 × 109/L; Neutrophil count, 1.80–6.30 × 109/L; Lymphocyte count, 1.10–3.20 × 109/L; Hemoglobin count, 130–175 g/L; Platelet count, 125–350 × 109/L
Statistical summary of the multivariate logistic regression model
| Variables | Coefficient | Std. error | Wald | OR (95% CI) |
|---|---|---|---|---|
| Time interval from symptoms onset to CT exams | 1.045 | 0.257 | 16.587 | 2.84 (1.72, 4.70) |
| Original_firstorder_Minimum | 0.740 | 0.619 | 1.430 | 2.10 (0.62, 7.04) |
| Original_gldm_SmallDependenceLowGrayLevelEmphasis | 0.187 | 0.297 | 0.397 | 1.21 (0.67, 2.16) |
| Original_glszm_LargeAreaHighGrayLevelEmphasis | 0.093 | 0.290 | 0.104 | 1.10 (0.62, 1.94) |
| Original_firstorder_10Percentile | 0.050 | 0.616 | 0.007 | 1.05 (0.31, 3.52) |
| Original_shape_Sphericity | − 0.007 | 0.279 | 0.001 | 0.99 (0.57, 1.72) |
| Original_gldm_LargeDependenceLowGrayLevelEmphasis | − 0.076 | 0.302 | 0.063 | 0.93 (0.51, 1.67) |
| Original_gldm_LargeDependenceHighGrayLevelEmphasis | − 0.123 | 0.350 | 0.122 | 0.88 (0.45, 1.76) |
| Original_glrlm_ShortRunHighGrayLevelEmphasis | − 0.183 | 0.328 | 0.306 | 0.83 (0.44, 1.59) |
| Original_shape_SurfaceArea | − 0.570 | 0.309 | 3.402 | 0.57 (0.31, 1.04) |
| Constant | 0.609 |
OR odds ratio, CI confidence interval
Fig. 4Rad scores for each patient in the training and testing cohorts
Fig. 5ROC curve in the training and testing datasets. ROC receiver operating characteristic
Fig. 6Calibration curve in the training and testing datasets. The y-axis shows the actual result. The x-axis represents the predicted probability. The diagonal dotted line represents an ideal model. The blue solid line indicates the performance of the model. The closer the blue solid line is to the diagonal dotted line, the better the prediction is
Fig. 7Decision curve analysis (DCA) in the training and testing datasets. The y-axis represents the net benefit (the net benefit was calculated by subtracting the proportion of all false-positive patients from the true-positive patient, and the weight is the relative hazard of abandoning treatment versus negative patients). The red solid line indicates the model. The black solid line indicates the hypothesis that all patients were treated by one scheme (for example, assuming that all patients were in the RT-PCR-negative group). The black dotted line represents the hypothesis that all patients were treated by another scheme (for example, assuming that all patients were in the RT-PCR positive group). The model shows the added net benefit if the probability thresholds in the training and testing datasets are more than 0.20 and between 0.15 and 0.82, respectively